Difference between revisions of "Letrozole (Femara)"
Jump to navigation
Jump to search
m |
|||
| Line 16: | Line 16: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *1997-07-25: Initial approval for the treatment of advanced [[breast cancer]] in postmenopausal women |
| − | *10 | + | *2004-10-29: Accelerated approval for the extended adjuvant treatment of early [[breast cancer]] in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. ''(Indication expanded to adjuvant setting after prior therapy; based on NCIC-CTG MA.17)'' |
| − | ** | + | **2010-04-30: Converted to regular approval. |
| − | *12 | + | *2005-12-28: Accelerated approval for the adjuvant treatment of postmenopausal women with [[Biomarkers#HR|hormone receptor]] [[Biomarkers#Expression|positive]] early [[breast cancer]]. ''(Indication expanded to adjuvant setting; based on BIG 1-98)'' |
| − | ** | + | **2010-04-30: Converted to regular approval. |
| − | * | + | *2010-03-02: Label simplified to adjuvant treatment of postmenopausal women with [[Biomarkers#HR|hormone receptor]] [[Biomarkers#Expression|positive]] early [[breast cancer]]. ''(No change)'' |
| − | * | + | *2010-03-02: Label simplified to extended adjuvant treatment of postmenopausal women with early [[breast cancer]] who have received prior standard adjuvant tamoxifen therapy. ''(Years requirement removed)'' |
| − | * | + | *2010-03-02: Label simplified to first and second-line treatment of postmenopausal women with [[Biomarkers#HR|hormone receptor]] [[Biomarkers#Expression|positive]] or [[Biomarkers#Unknown|unknown]] advanced [[breast cancer]]. ''(Based on ILBCG, AR/BC2, AR/BC3)'' |
| − | + | ==History of changes in Health Canada indication== | |
| + | *2005-04-01: Initial notice of compliance with conditions | ||
| + | *2010-12-17: Conditions were met | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' CGS 20267 | *'''Code name:''' CGS 20267 | ||
| Line 41: | Line 43: | ||
[[Category:Low-grade serous ovarian cancer medications]] | [[Category:Low-grade serous ovarian cancer medications]] | ||
| + | [[Category:EMA approved in 1996]] | ||
[[Category:FDA approved in 1997]] | [[Category:FDA approved in 1997]] | ||
| + | [[Category:Health Canada approved in 2005]] | ||
Revision as of 01:47, 30 March 2023
General information
Class/mechanism: Selective non-steroidal aromatase inhibitor. The aromatase enzyme converts adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues. Letrozole competitively binds to and inhibits the aromatase by binding to the heme of the enzyme's cytochrome P450.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Letrozole (Femara) package insert[1]
- Letrozole (Femara) patient drug information (Chemocare)[4]
- Letrozole (Femara) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1997-07-25: Initial approval for the treatment of advanced breast cancer in postmenopausal women
- 2004-10-29: Accelerated approval for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. (Indication expanded to adjuvant setting after prior therapy; based on NCIC-CTG MA.17)
- 2010-04-30: Converted to regular approval.
- 2005-12-28: Accelerated approval for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. (Indication expanded to adjuvant setting; based on BIG 1-98)
- 2010-04-30: Converted to regular approval.
- 2010-03-02: Label simplified to adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. (No change)
- 2010-03-02: Label simplified to extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. (Years requirement removed)
- 2010-03-02: Label simplified to first and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer. (Based on ILBCG, AR/BC2, AR/BC3)
History of changes in Health Canada indication
- 2005-04-01: Initial notice of compliance with conditions
- 2010-12-17: Conditions were met
Also known as
- Code name: CGS 20267
- Brand names: Femara, Fempro, Gynotril, Latrotal, Lerozol, Letoval, Letpro, Letromina, Letroplex, Letroz, Letrozol, Lexel, Lezole